日本におけるSGLT2阻害薬と腎性貧血：RWD

基本情報

NCT ID

NCT07063316

ステータス

実施中（募集終了）

試験のフェーズ

-

試験タイプ

観察

目標被験者数

15,000

治験依頼者名

Boehringer Ingelheim

概要

The objectives of the study are: 1. To compare the risk and timing of anemia onset between Sodium-Glucose Co-Transporter-2 (SGLT2) inhibitor users and non-users in patients with chronic kidney disease (CKD) from the index date to first event occurrence or the end date of each individual's follow-up. 2. To compare the following outcomes from the index date to 731 days (24 months) or the end date of each individual's follow-up: A) Longitudinal changes in laboratory values between SGLT2 inhibitor users and non-users in patients with CKD. B) Prescription patterns and treatment regimens for anemia between SGLT2 inhibitor users and non-users in patients with CKD, including analysis of medication types, dosing strategies, and duration of treatments. C) Anemia-related healthcare costs between SGLT2 inhibitor users and non-users.

対象疾患

介入

依頼者（Sponsor）

実施施設 (1)